-
EP3008039
European procedure
Extract from the Register of European Patents
EP About this file: EP3008039
| EP3008039 - CRYSTALLINE FORM OF A MDM2 INHIBITOR [Right-click to bookmark this link] | |||
| Former [2016/16] | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | ||
| [2020/23] | Status | No opposition filed within time limit Status updated on 17.09.2021 Database last updated on 19.07.2024 | |
| Former | The patent has been granted Status updated on 09.10.2020 | ||
| Former | Grant of patent is intended Status updated on 25.05.2020 | ||
| Former | Examination is in progress Status updated on 18.11.2016 | Most recent event Tooltip | 08.10.2021 | Lapse of the patent in a contracting state | published on 10.11.2021 [2021/45] | Applicant(s) | For all designated states AMGEN INC. One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US | [2020/45] |
| Former [2016/16] | For all designated states AMGEN, INC. One Amgen Center Drive Thousand Oaks, CA 91320 / US | Inventor(s) | 01 /
BIO, Matthew 433 E. Micheltorena Street Santa Barbara, CA 93101 / US | 02 /
CAILLE, Sebastien 11521 Gentlewood Drive Moorpark, CA 93021 / US | 03 /
COCHRAN, Brian 1680 Camino Olmo F Thousand Oaks, CA 91320 / US | 04 /
FANG, Yuanqing 7 Vincent Avenue Belmont, MA 02478 / US | 05 /
FOX, Brian, M. 124 Swallowtail Court Brisbane, CA 94005 / US | 06 /
LUCAS, Brian, S. 4 Brantwood Road Arlington, MA 02476 / US | 07 /
MCGEE, Lawrence, R. 39 Big Sur Way Pacifica, CA 94044 / US | 08 /
VOUNATSOS, Filisaty 1648 Fox Springs Circle Thousand Oaks, CA 91320 / US | 09 /
WIEDEMANN, Sean 29 Regent Street Cambridge, MA 02140 / US | 10 /
WORTMAN, Sarah 1370 Hollyburne Avenue Menlo Park, CA 94025 / US | [2016/16] | Representative(s) | Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE | [2016/16] | Application number, filing date | 14735785.9 | 09.06.2014 | [2016/16] | WO2014US41594 | Priority number, date | US201361833196P | 10.06.2013 Original published format: US 201361833196 P | [2016/16] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014200937 | Date: | 18.12.2014 | Language: | EN | [2014/51] | Type: | A1 Application with search report | No.: | EP3008039 | Date: | 20.04.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.12.2014 takes the place of the publication of the European patent application. | [2016/16] | Type: | B1 Patent specification | No.: | EP3008039 | Date: | 11.11.2020 | Language: | EN | [2020/46] | Search report(s) | International search report - published on: | EP | 18.12.2014 | Classification | IPC: | C07D211/76, A61K31/45, A61P35/00, C07C309/04, C07D498/04 | [2016/16] | CPC: |
C07C309/35 (EP,IL,US);
C07D211/94 (IL,US);
C07D211/76 (EA,IL,KR,US);
A61K31/451 (IL,KR,US);
A61K31/45 (EA,IL);
A61P35/00 (EA,IL,KR);
A61P35/02 (IL);
A61P43/00 (IL);
C07C309/04 (EA,IL,US);
C07C309/25 (IL,US);
C07C313/02 (IL,US);
C07D491/048 (IL,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/16] | Extension states | BA | 24.11.2015 | ME | 24.11.2015 | Title | German: | KRISTALLINE FORM EINES MDM2-INHIBITORS | [2020/23] | English: | CRYSTALLINE FORM OF A MDM2 INHIBITOR | [2020/23] | French: | FORME CRISTALLINE D'UN INHIBITEUR MDM2 | [2020/23] |
| Former [2016/16] | VERFAHREN ZUR HERSTELLUNG UND KRISTALLINE FORMEN EINES MDM2-INHIBITORS | ||
| Former [2016/16] | PROCESSES OF MAKING AND CRYSTALLINE FORMS OF A MDM2 INHIBITOR | ||
| Former [2016/16] | PROCÉDÉS DE PRODUCTION ET FORMES CRISTALLINES D'UN INHIBITEUR MDM2 | Entry into regional phase | 24.11.2015 | National basic fee paid | 24.11.2015 | Designation fee(s) paid | 24.11.2015 | Examination fee paid | Examination procedure | 24.11.2015 | Examination requested [2016/16] | 28.07.2016 | Amendment by applicant (claims and/or description) | 22.11.2016 | Despatch of a communication from the examining division (Time limit: M06) | 30.05.2017 | Reply to a communication from the examining division | 19.01.2018 | Despatch of a communication from the examining division (Time limit: M06) | 10.07.2018 | Reply to a communication from the examining division | 05.11.2019 | Despatch of a communication from the examining division (Time limit: M04) | 12.03.2020 | Reply to a communication from the examining division | 26.05.2020 | Communication of intention to grant the patent | 28.09.2020 | Fee for grant paid | 28.09.2020 | Fee for publishing/printing paid | 28.09.2020 | Receipt of the translation of the claim(s) | Divisional application(s) | EP20197741.0 / EP3805232 | Opposition(s) | 12.08.2021 | No opposition filed within time limit [2021/42] | Fees paid | Renewal fee | 10.06.2016 | Renewal fee patent year 03 | 16.06.2017 | Renewal fee patent year 04 | 27.06.2018 | Renewal fee patent year 05 | 27.06.2019 | Renewal fee patent year 06 | 29.06.2020 | Renewal fee patent year 07 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | AL | 11.11.2020 | [2021/45] | Cited in | International search | [XDI]WO2011153509 (AMGEN INC [US], et al); |